Medication-Assisted Treatment (MAT / MOUD)
FDA-approved medications — buprenorphine, methadone, and naltrexone — that treat opioid use disorder, usually alongside counseling.
SDG 3 Good Health & Well-beingWhat is it?
Medication-assisted treatment (MAT), increasingly called medications for opioid use disorder (MOUD), uses three FDA-approved medications — buprenorphine, methadone, and naltrexone — to treat opioid use disorder, typically combined with counseling and psychosocial support.
Why does it matter?
MOUD is the standard of care for opioid use disorder and is associated with substantially lower risk of overdose death and improved retention in treatment. It is one of the most effective interventions available for the condition.
How does it work?
Buprenorphine and methadone are opioid agonists that reduce cravings and withdrawal without producing the disruptive highs of misuse; naltrexone blocks opioid effects entirely. Stabilizing brain chemistry lets people rebuild work, family, and health.
Who benefits?
People with opioid use disorder benefit most directly through reduced overdose risk, and communities benefit from fewer deaths, less disease transmission, and more people in stable recovery.
Who may be disadvantaged?
People in rural areas may struggle to start MOUD because prescribers, opioid treatment programs, and pharmacies stocking these medications are scarce and often far away.
What evidence exists?
NIDA, SAMHSA, and a National Academies consensus report conclude that MOUD reduces mortality and improves retention, and that withholding it is inconsistent with the science and worsens outcomes.
What tradeoffs exist?
Agonist medications require adherence and ongoing prescribing capacity, and methadone dosing is tightly regulated; these logistics are harder to sustain where the clinical workforce is thin.
Common misconceptions
MOUD is not “trading one addiction for another” — under medical supervision it restores function and lowers death risk, which abstinence alone often does not for opioid use disorder.
What you can do next
Review the buprenorphine-retention research and the hub-and-spoke case study for how MOUD is delivered, and the rural access barriers that limit its reach.